BRCA1 and breast cancer: PM yields a risk reducing effect of more than 90-100% in healthy BRCA1 and BRCA2 mutation carriers [25-27] and PBSO decreases breast cancer risk in BRCA mutation carriers without prior breast cancer approximately by 50% [26, 28, 29].